Medtronic upgraded by UBS with a new price target
$MDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
UBS upgraded Medtronic from Sell to Neutral and set a new price target of $90.00 from $76.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $110.00 | Outperform | Leerink Partners |
| 3/4/2025 | $92.00 → $107.00 | Neutral → Buy | Citigroup |
| 10/10/2024 | $98.00 → $105.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 8/21/2024 | $92.00 → $94.00 | Perform | Oppenheimer |
| 8/15/2024 | $76.00 → $90.00 | Sell → Neutral | UBS |
| 8/14/2024 | $100.00 → $85.00 | Buy → Hold | Stifel |
| 5/30/2024 | $83.00 | Sell | Goldman |
| 7/19/2023 | $90.00 | Neutral | Robert W. Baird |
4 - Medtronic plc (0001613103) (Issuer)
3 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
Leerink Partners initiated coverage of Medtronic with a rating of Outperform and set a new price target of $110.00
Citigroup upgraded Medtronic from Neutral to Buy and set a new price target of $107.00 from $92.00 previously
RBC Capital Mkts upgraded Medtronic from Sector Perform to Outperform and set a new price target of $105.00 from $98.00 previously